Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Ontario Institute for Cancer Research makes three equity investments

Abstract:
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research (OICR) today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

Ontario Institute for Cancer Research makes three equity investments

Ontario, Canada | Posted on April 26th, 2010

"These technologies hold exceptional promise in the advancement of personalized cancer medicine," said Mr. Stonebanks. "The investments will help close the gap between seed funding and clinical proof of concept, moving these programs closer to the commercial arena."

"The OICR has quickly established itself as a global leader in research commercialization," said John Milloy, Ontario Minister of Research and Innovation. "The Ontario government continues to support OICR as it invests in health technologies and strengthens Ontario as an innovation-based economy and society."

Dr. Li Zhang, Senior Scientist in the Division of Cellular and Molecular Biology at the University Health Network's Toronto General Research Institute, received the investment for her novel cellular immunotherapy for cancer.

OICR and the University Health Network created a new spin-off company to complete the pre-clinical requirements to test Dr. Zhang's novel cellular therapy in patients with acute myeloid leukemia (AML), a disease which has seen few improvements in therapy in the last 40 years. This proprietary UHN technology involves the growth of a specific minor population of the patient's own cancer-killing T cells in the laboratory with subsequent reinfusion into the patient to fight their disease. Dr. Zhang's group has performed extensive pre-clinical testing of these cancer-killing cells grown from AML patients and has shown that they kill human leukemia cells in an animal model. The next step is a phase I clinical trial in AML patients.

DVS Sciences Inc., a spin-off company from the University of Toronto, will use OICR's investment to support further engineering and product development of its revolutionary instrument for highly multiplexed biomarker analysis for scientific research, clinical trials and personalized medicine. The machine is similar to a flow cytometer but instead of fluorescent tags, which limit the multiplex capacity due to spectral overlap, the DVS system uses stable isotope tags to identify up to 100 biomarkers at a time with very high resolution and dynamic range. The system has been demonstrated analyzing 30 biomarkers simultaneously in single human leukemia cells at a rate of 1,000 cells per second with absolute signal quantification. Several prototypes have been sold to top laboratories in the U.S.A. and Canada. Also under development by DVS is a low-cost liquid bead array for gene analysis with multiplex capability in the hundreds of thousands - far beyond that of today's fluorescent-based bead arrays and approaching that of "gene chip" microarrays but at a fraction of the cost.

Dr. Shana Kelley, Director of the Division of Biomolecular Sciences in the Faculty of Pharmacy at the University of Toronto and Dr. Ted Sargent, Professor in the Edward S. Rogers Sr. Department of Electrical and Computer Engineering at the University of Toronto, and Canada Research Chair in Nanotechnology, received an investment for their validation of a microchip-based diagnostic system for clinically accepted leukemia biomarkers.

Plans are being made for the technology to be advanced by a start-up company with seed funding coming from OICR and other groups. OICR's investment will facilitate testing and refinement of the sensitive electronic chip and hand-held device for direct and rapid detection of clinically relevant biomolecules in patient samples. The chip-based system uses no enzymatic amplification steps and provides electronic detection of biomolecules (DNA, RNA or protein) in five minutes with high specificity and at concentrations as low as 100 molecules per sample. The single-use detector chips feature simple, inexpensive silicon-based integrated circuit technology, multiplex and multiple sample type capability, and integrated sample pre-processing.

OICR had previously invested in the three projects through its Intellectual Property Development and Commercialization Program, which provides seed funding for late stage academic projects that meet specific market-oriented criteria.

####

About Ontario Institute for Cancer Research
OICR is a new, innovative cancer research & development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. OICR supports 500 scientific staff and trainees (located at its headquarters and in research institutes and academia across the Province of Ontario) and an $85 million annual operating budget. It has key research efforts underway in small molecules, biologics, cancer stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase I clinical trials.

OICR is making Ontario more effective in knowledge transfer and commercialization, to maximize health and economic benefits of research findings for the people of Ontario. For more information, please visit the website at www.oicr.on.ca/commercialization.

For more information, please click here

Contacts:
Rhea Cohen
Director of Communications

Telephone: (416) 673-6642
Mobile: (416) 671-2846

Copyright © Newswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Report highlights opportunities and risks associated with synthetic biology and bioengineering November 22nd, 2017

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

Nano Global, Arm Collaborate on Artificial Intelligence Chip to Drive Health Revolution by Capturing and Analyzing Molecular Data in Real Time November 21st, 2017

Govt.-Legislation/Regulation/Funding/Policy

EC Project Aims at Creating and Commercializing Cyber-Physical-System Solutions November 14th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Leti Joins DARPA-Funded Project to Develop Implantable Device for Restoring Vision November 9th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

Academic/Education

LuleŚ University of Technology is using the Deben CT5000TEC stage to perform x-ray microtomography experiments with the ZEISS Xradia 510 Versa to understand deformation and strain inside inhomogeneous materials November 7th, 2017

Park Systems Announces the Grand Opening of the Park NanoScience Center at SUNY Polytechnic Institute November 3rd, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

Moving at the Speed of Light: University of Arizona selected for high-impact, industrial demonstration of new integrated photonic cryogenic datalink for focal plane arrays: Program is major milestone for AIM Photonics August 10th, 2017

Investments/IPO's/Splits

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Nanomedicine

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

A new way to mix oil and water: Condensation-based method developed at MIT could create stable nanoscale emulsions November 8th, 2017

Announcements

Report highlights opportunities and risks associated with synthetic biology and bioengineering November 22nd, 2017

Quantum optics allows us to abandon expensive lasers in spectroscopy: Lomonosov Moscow State University scientists have invented a new method of spectroscopy November 21st, 2017

Nano-watch has steady hands November 21st, 2017

Nano Global, Arm Collaborate on Artificial Intelligence Chip to Drive Health Revolution by Capturing and Analyzing Molecular Data in Real Time November 21st, 2017

Nanobiotechnology

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3ís significant potential role in Immuno-Oncology at SITC Annual Meeting November 14th, 2017

Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference November 14th, 2017

Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs November 8th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project